» Articles » PMID: 10388474

Estimation of Prostate Cancer Probability by Logistic Regression: Free and Total Prostate-specific Antigen, Digital Rectal Examination, and Heredity Are Significant Variables

Overview
Journal Clin Chem
Specialty Biochemistry
Date 1999 Jul 1
PMID 10388474
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Despite low specificity, serum prostate-specific antigen (PSA) is widely used in screening for prostate cancer. Specificity can be improved by measuring free and total PSA and by combining these results with clinical findings. Methods such as neural networks and logistic regression are alternatives to multistep algorithms for clinical use of the combined findings.

Methods: We compared multilayer perceptron (MLP) and logistic regression (LR) analysis for predicting prostate cancer in a screening population of 974 men, ages 55-66 years. The study sample comprised men with PSA values >3 microg/L. Explanatory variables considered were age, free and total PSA and their ratio, digital rectal examination (DRE), transrectal ultrasonography, and a family history of prostate cancer.

Results: When at least 90% sensitivity in the training sets was required, the mean sensitivity and specificity obtained were 87% and 41% with LR and 85% and 26% with MLP, respectively. The cancer specificity of an LR model comprising the proportion of free to total PSA, DRE, and heredity as explanatory variables was significantly better than that of total PSA and the proportion of free to total PSA (P <0.01, McNemar test). The proportion of free to total PSA, DRE, and heredity were used to prepare cancer probability curves.

Conclusion: The probability calculated by logistic regression provides better diagnostic accuracy for prostate cancer than the presently used multistep algorithms for estimation of the need to perform biopsy.

Citing Articles

LncRNA EGOT/miR-211-5p Affected Radiosensitivity of Rectal Cancer by Competitively Regulating ErbB4.

Li C, Liu H, Wei R, Liu Z, Chen H, Guan X Onco Targets Ther. 2021; 14:2867-2878.

PMID: 33953571 PMC: 8091867. DOI: 10.2147/OTT.S256989.


[Parameters to improve the specificity of the prostate-specific antigen. Early detection of prostate cancer].

Borgermann C, Kliner S, Swoboda A, Luboldt H, Rubben H Urologe A. 2011; 50(9):1095-100.

PMID: 21567277 DOI: 10.1007/s00120-011-2577-8.


Critical review of prostate cancer predictive tools.

Shariat S, Kattan M, Vickers A, Karakiewicz P, Scardino P Future Oncol. 2009; 5(10):1555-84.

PMID: 20001796 PMC: 2933457. DOI: 10.2217/fon.09.121.


The value of an artificial neural network in the decision-making for prostate biopsies.

Meijer R, Gemen E, van Onna I, van der Linden J, Beerlage H, Kusters G World J Urol. 2009; 27(5):593-8.

PMID: 19562346 DOI: 10.1007/s00345-009-0444-7.


Using biopsy to detect prostate cancer.

Shariat S, Roehrborn C Rev Urol. 2009; 10(4):262-80.

PMID: 19145270 PMC: 2615104.